In vitro antifungal susceptibilities of Candida isolates from patients with invasive candidiasis in Kuala Lumpur Hospital, Malaysia

Journal of Medical Microbiology

Volumn 60, Issue 9, 2011, Pages 1312-1316

  Amran, Fairuz ^a   Aziz, M Nazri ^b   Ibrahim, Hishamshah M ^b   Atiqah, N H ^a   Parameswari, S ^a   Hafiza, M R ^a   Ifwat, M ^a  

^a INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

^b HOSPITAL KUALA LUMPUR   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA FAMATA; CANDIDA GLABRATA; CANDIDA INCONSPICUA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDA VALIDA; CLAVISPORA LUSITANIAE; FUNGUS ISOLATION; IN VITRO STUDY; INVASIVE CANDIDIASIS; MALAYSIA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA GUILLIERMONDII; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, INVASIVE; DRUG RESISTANCE, FUNGAL; HOSPITALS; HUMANS; MALAYSIA; MICROBIAL SENSITIVITY TESTS;

EID: 80051721933     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.027631-0     Document Type: Article

References (24)

1. Anaissie, E. J., Paetznick, V. L., Ensign, L. G., Espinel-Ingroff, A., Galgiani, J. N., Hitchcock, C. A., LaRocco, M., Patterson, T., Pfaller, M. A. & other authors (1996). Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study. Antimicrob Agents Chemother 40, 2387-2391.
2. Blot, S., Vandewoude, K. & Vogelaers, D. (2008). Discriminating invasive fungal infection from colonization. Crit Care 12, 412, author reply 412.
3. Bodey, G. P., Mardani, M., Hanna, H. A., Boktour, M., Abbas, J., Girgawy, E., Hachem, R. Y., Kontoyiannis, D. P. & Raad, I. I. (2002). The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 112, 380-385.
4. Cheung, C., Guo, Y., Gialanella, P. & Feldmesser, M. (2006). Development of candidemia on caspofungin therapy: a case report. Infection 34, 345-348.
5. Chong, P. P., Lee, Y. L., Tan, B. C. & Ng, K. P. (2003). Genetic relatedness of Candida strains isolated from women with vaginal candidiasis in Malaysia. J Med Microbiol 52, 657-666.
6. CLSI (2008). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, 3rd edn. Approved standard M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute.
7. Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N. & Wenzel, R. P. (1999). Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 29, 239-244.
8. Forrest, G. N., Weekes, E. & Johnson, J. K. (2008). Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 56, 126-129.
9. Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A. & other authors (1999). The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 29, 1164-1170.
10. Mokaddas, E. M., Al-Sweih, N. A. & Khan, Z. U. (2007). Species distribution and antifungal susceptibility of Candida bloodstream isolates in Kuwait: a 10-year study. J Med Microbiol 56, 255-259.
11. Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N. & other authors (2002). Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347, 2020-2029.
12. Morgan, J. (2005). Global trends in candidemia: review of reports from 1995-2005. Curr Infect Dis Rep 7, 429-439.
13. Ng, K. P., Madasamy, M., Saw, T. L., Baki, A., He, J. & Soo-Hoo, T. S. (1998). Candida biotypes isolated from clinical specimens in Malaysia. Mycopathologia 144, 135-140.
14. Ostrosky-Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N., Kauffman, C. A. & other authors (2003). Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47, 3149-3154.
15. Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Hollis, R. J. & Messer, S. A. for The SENTRY Participant Group (1998). International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. J Clin Microbiol 36, 1886-1889.
16. Pfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B. & Wenzel, R. P. (1998b). National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic Importance. Diagn Microbiol Infect Dis 30, 121-129.
17. Pfaller, M. A., Diekema, D. J., Rinaldi, M. G., Barnes, R., Hu, B., Veselov, A. V., Tiraboschi, N., Nagy, E. & Gibbs, D. L. (2005). Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 43, 5848-5859.
18. Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S. & Diekema, D. J. (2006). In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 44, 760-763.
19. Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S. & Diekema, D. J. (2008). In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46, 150-156.
20. Rangel-Frausto, M. S., Wiblin, T., Blumberg, H. M., Saiman, L., Patterson, J., Rinaldi, M., Pfaller, M., Edwards, J. E., Jr, Jarvis, W. & other authors (1999). National Epidemiology of Mycoses Survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 29, 253-258.
21. Rex, J. H., Pfaller, M. A., Galgiani, J.N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G. &other authors (1997). Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 24, 235-247.
22. Ruan, S.-Y., Chu C.-C. & Hsueh, P.-R. (2008). In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. Antimicrob Agents Chemother 52, 2919-2922.
23. Wenzel, R. P. & Edmond, M. B. (2001). Severe sepsis-national estimates. Crit Care Med 29, 1472-1474.
24. Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P. & Edmond, M. B. (2004). Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39, 309-317.